13F HOLDINGS REPORT
Aisling Capital Management LP
Quarter ended Q2 2023 · Filed May 9, 2023 · Accession 0001766721-23-000002
Total Value
$207.8M
Positions
16
Other Managers
0
Confidential Omitted
No
Holdings (16)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 6,068,125 | $100.6M | 48.41% |
| 2 | Biomea Fusion Inc. (BMEA) | BMEA | 798,757 | $24.8M | 11.92% |
| 3 | Verona Pharma plc (VRNA) | 925050106 | 1,115,352 | $22.4M | 10.78% |
| 4 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 1,025,000 | $21.6M | 10.42% |
| 5 | Monte Rosa Therapeutics Inc. (GLUE) | GLUE | 1,472,331 | $11.5M | 5.52% |
| 6 | Elevation Oncology Inc. (ELEV) | 28623U101 | 2,834,910 | $5.4M | 2.59% |
| 7 | Reneo Pharmaceuticals Inc. (RPHM) | 75974E103 | 886,075 | $5.3M | 2.55% |
| 8 | Nuvation Bio Inc. (NUVB) | NUVB | 2,541,009 | $4.2M | 2.03% |
| 9 | Aclaris Theraputics Inc. (ACRS) | ACRS | 434,455 | $3.5M | 1.69% |
| 10 | Poseida Therapeutics Inc. (PSTX) | 73730P108 | 1,043,267 | $3.2M | 1.55% |
| 11 | Spruce Biosciences, Inc. (SPRB) | SPRB | 1,205,511 | $2.7M | 1.28% |
| 12 | AVROBIO, Inc. (AVRO) | 05455M100 | 1,009,779 | $1.0M | 0.49% |
| 13 | Aeglea Biotherapeutics Inc. (AGLE) | 00773J103 | 1,691,151 | $490,434 | 0.24% |
| 14 | Viracta Therapeutics Inc. (VIRX) | 92765F108 | 288,571 | $458,828 | 0.22% |
| 15 | Atreca Inc. (BCEL) | 04965G109 | 387,653 | $441,924 | 0.21% |
| 16 | Marker Therapeutics, Inc. (MRKR) | MRKR | 314,286 | $223,143 | 0.11% |